McDonald Fellowship recipients 2022
The McDonald Fellowships enable young researchers from low- and middle-income countries to work in a research institution outside their own country, with a view to returning to their country to establish an MS research program involving the application of their newly learned techniques.
MSIF-ECTRIMS McDonald Fellowship
Dr Kshiteeja Jain from India was awarded the 2022 MSIF-ECTRIMS McDonald Fellowship. Dr Jain will conduct a project on “Integration of functional network abnormalities and structural MRI changes to classify MS cognitive phenotypes” at the San Raffaele Scientific Institute in Milan, Italy, under the supervision of Dr. Maria A. Rocca.
Dr Jain is sponsored by our partner the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
MSIF-ARSEP McDonald Fellowship
Dr Agustin Pappolla from Argentina was awarded the 2022 MSIF-ARSEP McDonald Fellowship. Dr Pappolla will conduct a project on “Correlation of serum biomarkers and treatment response scoring systems for early treatment assessment in highly aggressive multiple sclerosis” at Cemcat, Barcelona, Spain under supervision of Professor Xavier Montalban.
This Fellowship is sponsored by our partner, the Fondation d’Aide pour la Recherche sur la Sclerose en Plaques (ARSEP).
We are tremendously grateful for the support and continued partnership of ARSEP and ECTRIMS. Without them, these fellowships would not be possible.
2022 Du Pré Grant recipients
Dr Enkhzaya Chuluunbaatar from Mongolia will be working with Professor Helen Tremlett at the University of British Columbia, Canada on a project titled: “A Systematic Review of Comorbidities Associated with Disease outcomes in Multiple Sclerosis”.
Dr Gabriela Girafa from Brazil will be working with Prof Axel Petzold at the Moorfields eye hospital in London, United Kingdom on a project titled “Early treatment in Myelin Oligodendrocyte Glycoprotein antibody associated Optic Neuritis”.
Dr Mariano Marrodan from Argentina will be working with Professor Xavier Montalban to validate treatment response scoring systems in naive patients treated with high-efficacy disease modifying drugs at Cemcat in Barcelona, Spain.